



Julia R. Ferrante, Ph.D.

Patent Agent

julia.ferrante@icemiller.com

215 446 3915

Drawing on her interdisciplinary background in pharmacology, neuroscience, and molecular biology, Julia Ferrante conducts due diligence, patentability, and freedom-to-operate analyses. She also prepares and prosecutes domestic and international patent applications.

Julia brings a scientific perspective to intellectual property matters involving life sciences and emerging therapeutic technologies. Her doctoral research identified novel therapeutic targets for the treatment of acute opioid withdrawal in infants and characterized the neurobiological alterations induced by neonatal opioid exposure. She has authored multiple peer-reviewed publications and has presented her research to scientific audiences at both local and international conferences.

Julia is licensed to practice patent law exclusively before the United States Patent and Trademark Office (USPTO) and represents both foreign and domestic clients before the USPTO in the area of patent prosecution. Julia is not licensed to practice before state and federal court.

Education

- Villanova University (B.S., *magna cum laude*, 2020)
 - Cognitive and Behavioral Neuroscience
- University of Pennsylvania (Ph.D, 2026)
 - Pharmacology

Admissions

- United States Patent and Trademark Office

Professional Affiliations

- American Intellectual Property Law Association
- Benjamin Franklin American Inn of Court
- American Society for Pharmacology and Experimental Therapeutics (ASPET)

Services & Industries

- Intellectual Property
- Life Sciences & Biotechnology
- IP Litigation
- Patents

Awards & Honors

- Ruth L. Kirschstein National Research Service Award Predoctoral Fellowship, National Institutes of Health, 2023
- Goldwater Scholarship, 2019

Published In

- “Perinatal morphine exposure induces chromatin and transcriptomic remodeling to alter immune and metabolic function,” *Frontiers in Immunology*, 2026
- “Microglia ablation is sufficient to prevent spontaneous withdrawal following perinatal morphine exposure,” *Brain, Behavior, and Immunity*, 2026
- “Advances in animal models of prenatal opioid exposure,” *Trends in Neurosciences*, 2024
- “Molecular and Long-Term Behavioral Consequences of Neonatal Opioid Exposure and Withdrawal in Mice,” *Frontiers in Behavioral Neuroscience*, 2023
- “Oxidative stress induces ceramide accumulation and lysosomal membrane permeabilization in retinal pigment epithelial cells,” *Disease Models and Mechanisms*, 2022
- “Paternal nicotine taking elicits heritable sex-specific phenotypes that are mediated by hippocampal Satb2,” *Molecular Psychiatry*, 2022

Speaking Engagements

- “Prenatal opioid exposure and its molecular, cellular, and behavioral outcomes,” International Narcotics Research Conference, Bologna, IT, 2025
- “Investigation of acute and long-term neuroimmune changes induced by early-life opioid exposure and withdrawal,” International Narcotics Research Conference, Atlanta, GA, 2023
- “Investigation of acute and long-term neuroimmune changes induced by early-life opioid exposure and withdrawal,” Mid-Atlantic Pharmacology Society Annual Meeting, Philadelphia, PA, 2022